Maastricht, The Netherlands, 1stAugust 2019 – Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces that Dr Werner Cautreels is joining the Company’s supervisory board taking on the role of Chairman. Dr Cautreels succeeds Simon Sturge, who steps down […]
Oncology Virtual Partnering
September 22-24 2020 Oncology Virtual Partnering Digital
BioPharm America
September 21-24 2020 BioPharm America Digital
Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform
Horizon 2020 INNOSUP grant allows the funding of a highly skilled and experienced researcher (Innovation Associate) to develop and implement state-of-art (bio)analytical methodologies for further understanding of the biological behaviour of CriPec® nanomedicines Maastricht, The Netherlands, 2nd July 2020 – Cristal Therapeutics, a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer […]
Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small
Small publication demonstrates that superior therapeutic profiles of CriPec® nanomedicines result from rational design Maastricht, The Netherlands, 11th May 2020 – Cristal Therapeutics, a Phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces the publication of a paper on its CriPec® nanomedicine technology […]
BIO-Europe 2019
November 11-13 BIO-Europe Hamburg, Germany
PODD
October 7-8 PODD Boston, USA
ESMO Annual Congress 2019
September 27 – October 1 ESMO Annual Congress 2019 Barcelona, Spain
EACR: Nanotechnology in Cancer
September 12-14 EACR: Nanotechnology in Cancer Cambridge, UK
Nordic Life Sciences
September 10-12 Nordic Life Sciences Malmö, Sweden
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer
Maastricht, The Netherlands, 1stAugust 2019 – Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces that Dr Werner Cautreels is joining the Company’s supervisory board taking on the role of Chairman. Dr Cautreels succeeds Simon Sturge, who steps down […]